Literature DB >> 22012181

Venous and arterial thrombosis in dialysis patients.

Gurbey Ocak1, Carla Y Vossen, Joris I Rotmans, Willem M Lijfering, Frits R Rosendaal, Karien J Parlevliet, Ray T Krediet, Els W Boeschoten, Friedo W Dekker, Marion Verduijn.   

Abstract

Whether the risk of both venous and arterial thrombosis is increased in dialysis patients as compared to the general population is unknown. In addition, it is unknown which subgroups are at highest risk. Furthermore, it is unknown whether having a history of venous thrombosis or arterial thrombosis prior to dialysis treatment increases mortality risk. A total of 455 dialysis patients were followed for objectively verified symptomatic thrombotic events between January 1997 and June 2009. The incidence rates in dialysis patients as compared to the general population was 5.6-fold (95% CI 3.1-8.9) increased for venous thrombosis, 11.9-fold (95% CI 9.3-14.9) increased for myocardial infarction, and 8.4-fold (95% CI 5.7-11.5) increased for ischaemic stroke. The combination of haemodialysis, lowest tertile of albumin, history of venous thrombosis, and malignancy was associated with subsequent venous thrombosis. Increased age, renal vascular disease, diabetes, high cholesterol levels, history of venous thrombosis, and history of arterial thrombosis were associated with subsequent arterial thrombosis. The all-cause mortality risk was 1.9-fold (95% CI 1.1-3.3) increased for patients with a history of venous thrombosis and 1.9-fold (95% CI 1.4-2.6) increased for patients with a history of arterial thrombosis. A potential limitation of this study was that in some risk categories associations with venous thrombosis did not reach statistical significance due to small numbers. In conclusion, dialysis patients have clearly elevated risks of venous thrombosis and arterial thrombosis and occurrence of venous thrombosis or arterial thrombosis prior to the start of dialysis is associated with an increased mortality risk.

Entities:  

Mesh:

Year:  2011        PMID: 22012181     DOI: 10.1160/TH11-06-0422

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts.

Authors:  Chih-Cheng Wu; Mu-Yang Hsieh; Szu-Chun Hung; Ko-Lin Kuo; Tung-Hu Tsai; Chao-Lun Lai; Jaw-Wen Chen; Shing-Jong Lin; Po-Hsun Huang; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2015-10-09       Impact factor: 10.121

2.  A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.

Authors:  Sian Robinson; Aleksander Zincuk; Ulla Lei Larsen; Claus Ekstrøm; Palle Toft
Journal:  Trials       Date:  2014-06-13       Impact factor: 2.279

Review 3.  Impact of Indoxyl Sulfate on Progenitor Cell-Related Neovascularization of Peripheral Arterial Disease and Post-Angioplasty Thrombosis of Dialysis Vascular Access.

Authors:  Chih-Cheng Wu; Szu-Chun Hung; Ko-Lin Kuo; Der-Cherng Tarng
Journal:  Toxins (Basel)       Date:  2017-01-07       Impact factor: 4.546

4.  Misdiagnosis for right atrial mass: a case report.

Authors:  Martha Alehli Rangel-Hernández; Alberto Aranda-Fraustro; Gabriela Melendez-Ramirez; Nilda Espínola-Zavaleta
Journal:  Eur Heart J Case Rep       Date:  2018-01-24

Review 5.  Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs.

Authors:  Orly Leiva; Roelof H Bekendam; Brenda D Garcia; Cristal Thompson; Alan Cantor; Vipul Chitalia; Katya Ravid
Journal:  TH Open       Date:  2019-06-07

6.  Terminal Phase Components of the Clotting Cascade in Patients with End-Stage Renal Disease Undergoing Hemodiafiltration or Hemodialysis Treatment.

Authors:  Krisztina Pénzes; Boglárka Hurják; Éva Katona; Gergely Becs; József Balla; László Muszbek
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

7.  Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis.

Authors:  Gurbey Ocak; Rianne Boenink; Marlies Noordzij; Willem Jan W Bos; Bjorn E Vikse; Aleix Cases; Julia Kerschbaum; Jaakko Helve; Maurizio Nordio; Mustafa Arici; Lucile Mercadal; Christoph Wanner; Runolfur Palsson; Kristine Hommel; Johan De Meester; Myrto Kostopoulou; Rafael Santamaria; Emilio Rodrigo; Helena Rydell; Samira Bell; Ziad A Massy; Kitty J Jager; Anneke Kramer
Journal:  JAMA Netw Open       Date:  2022-04-01

8.  Safety and effectiveness of apixaban compared to warfarin in dialysis patients.

Authors:  Daniel Reed; Surabhi Palkimas; Rebecca Hockman; Sumner Abraham; Tri Le; Hillary Maitland
Journal:  Res Pract Thromb Haemost       Date:  2018-03-26

9.  Coagulation Abnormalities in Renal Pathology of Chronic Kidney Disease: The Interplay between Blood Cells and Soluble Factors.

Authors:  Efthimia G Pavlou; Hara T Georgatzakou; Sotirios P Fortis; Konstantina A Tsante; Andreas G Tsantes; Efrosyni G Nomikou; Athanasia I Kapota; Dimitrios I Petras; Maria S Venetikou; Effie G Papageorgiou; Marianna H Antonelou; Anastasios G Kriebardis
Journal:  Biomolecules       Date:  2021-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.